stockrowNeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +72.1%
- Free cash flow
- −3,724.2%
- Total debt
- +10.9%
Quarter to September 2026, against a year earlier
Follow NEO
Alert me
NeoGenomics, Inc. (NEO) Current ratio
NeoGenomics, Inc.'s current ratio at the end of the quarter to 30 September 2026 was 3.5×, down 0.7× from fiscal 2025 (4.3×). Over the past ten years it has ranged from 1.7× (fiscal 2018) to 7.8× (fiscal 2021); the current reading is higher than 55% of that period. That is above the Diagnostics & Research industry median of 2.3× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 4.3× | 115.39% |
| FY2024 | 2.0× | (68.07%) |
| FY2023 | 6.2× | (7.92%) |
| FY2022 | 6.7× | (13.85%) |
| FY2021 | 7.8× | 27.42% |
| FY2020 | 6.1× | 34.77% |
| FY2019 | 4.5× | 167.37% |
| FY2018 | 1.7× | (27.73%) |
| FY2017 | 2.4× | 13.85% |
| FY2016 | 2.1× | 0.59% |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 3.5× | (2.02%) |
| Jun 2026 | 3.6× | (18.44%) |
| Mar 2026 | 4.4× | 3.67% |
| Dec 2025 | 4.3× | 9.04% |
| 43 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| VCYT Veracyte, Inc. compare | 5.6× |
| CSTL Castle Biosciences, Inc. compare | 5.3× |
| OPK OPKO Health, Inc. compare | 5.0× |
| PSNL Personalis, Inc. compare | 4.5× |
| ADPT Adaptive Biotechnologies Corporation compare | 4.0× |
| NEO NeoGenomics, Inc. | 3.5× |
| WGS GeneDx Holdings Corp. compare | 3.3× |
| CDNA CareDx, Inc. compare | 2.3× |
| FRNM Freenome, Inc compare | 0.2× |
| Diagnostics & Research industry median | 2.3× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on NEO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement